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The aim of this study was to clarify whether specific p53 mutations may have
biological relevance in terms of disease relapse or death in gastric carcinomas (GC).
Resected specimens from a consecutive series of 62 patients with GC undergoing
potentially curative surgery were prospectively studied. The mutational status of
exons 5–8 of the p53 gene was investigated in 62 cases using the PCR-SSCP and
sequencing. Presence of microsatellite instability (MSI) was evaluated in 56 cases
by analyzing loci highly sensitive ofMSI. Twentymutations of p53were detected in
17 of the 62 cases analyzed (27%). Ten mutations (50%) occurred in highly
conserved domains. According to the p53 specific functional domains: 4/20
mutations (20%)were in the L3 loop and3/20 (15%) in LSHmotif. Eight of the56GC
resultedMSI-H, 5 (9%) MSI-L, and 43 (77%)MSI stable (MSS). None of the 8 (14%)
MSI-H GC showed p53 mutations. p53 mutations were associated with intestinal
histotype. Moreover, specific mutations in functional domain (L3 and LSH),
together with advanced TNM stage, node involvement, depth of invasion, diffuse
histotype, proved to be significantly related to quicker relapse and to shorter overall
survival. Specificmutations in p53 functional domains, rather than anymutations in
this gene, may be biologically more significant in terms of patients outcome,
indicating that these mutations might have biological relevance to identify
subgroups of patients at higher risk of relapse or death who might benefit from a
more aggressive therapeutic approach. J. Cell. Physiol. 200: 476–485, 2004.
 2004 Wiley-Liss, Inc.
Despite a decreasing trend in incidence and mortality
inmostdeveloped countries, gastric carcinomas (GC) was
still recently estimated to represent the fourth most
common cancer in the world and the second leading cause
of cancer death (Gonzalez et al., 2000). Moreover, this
neoplasia still leads to an unfavorable prognosis, with a
relative 5-year survival rate varying from 5% to 15% in
the Western world. In adenocarcinomas, which represent
over 95% of GCs, distinct morphological, histological, and
biomolecular features have been observed, with the
result that a great many classification systems for GC
have been devised in the attempt to identify patient
subgroups with different prognostic features.
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Lauren (1965) classified GC into two groups: (1) an
intestinal, differentiated type, forming tubular or papil-
lary structures, and (2) a diffuse undifferentiated type,
where such structures are almost entirely absent
(Stadtlander and Waterbor, 1999; Endoh et al., 2000).
The last 20 years have seen an increase in the incidence of
diffuse-type GCs (Borch et al., 2000), which generally
lead to an unfavorable outcome (Karpeh et al., 2001);
nevertheless, patients with identical histopathological
features may follow a completely different clinical course.
From the biomolecular point of view, it has now been
established that carcinogenesis also in GCs is a multi-
step process where a series of genetic alterations
accumulate until they produce a neoplastic phenotype
(Fiocca et al., 2001). At least two pathways of genomic
instability have been identified in gastric carcinogen-
esis. The first pathway is characterized by the successive
accumulation of mutations in oncogenes and tumor
suppressor genes controlling epithelial cell growth and
differentiation. In particular, p53 mutations have been
quite frequently seen in GC (20–50% of cases), mostly
presenting as puntiform mutations in exons 5–8 (Prives
and Hall, 1999; Fenoglio-Preiser et al., 2003). This
region is made up of about 600 bp and contains several
areas which have been highly conserved during evolu-
tion, together with a great many functional domains,
among which the L2 loop, which is needed for the correct
folding and stabilization of the central part of the
protein, the L3 loop and the L1 loop-sheet-helix motif
(LSH), directly involved in interaction between the
protein and the DNA (Cho et al., 1994). It has been
reported that p53 alterations are often associated with
greater invasiveness of tumors (Sakurai et al., 1995; Aas
et al., 1996) and particular attention has recently been
paid to the prognostic role played by specific alterations
of the gene p53 (in conserved areas or in functional
domains) in several types of human neoplasias (color-
ectal, lung and breast cancers) (Borresen et al., 1995;
Borresen-Dale et al., 1998; Skaug et al., 2000; Russo
et al., 2002).
The second pathway of genomic instability, known as
microsatellite instability (MSI) pathway, is character-
ized by the accumulation of somatic alteration in the
length of simple nucleotide repeats (microsatellite)
mostly consisting in small deletions/insertions that
affect short repeated DNA sequences in either coding
or non-coding regions (Simpson et al., 2001). These short
repeated sequences include mononucleotide repeats,
that typically manifest contractions, as well as di-, tri-,
and tetranucleotide repeats that may show either
contractions or expansions. Since di-, tri-, and tetra-
nucleotide repeats manifest infrequently high levels of
instability, the presence of alterations at these repeats is
considered as indicator of low level of instability (MSI-
L), whereas contractions at mononucleotide repeats is
considered the hallmark of the MSI-high (MSI-H)
phenotype. Tumors presenting MSI-H have a deficit
of the mismatch repair system (MMR) (Breivik and
Gaudernack, 1999), present karyotype stability, and
follow progression pathway(s) characterized by the
accumulation of frameshift mutations at coding repeti-
tive sequences within genes whose products play roles at
different levels in the control of cell growth, apoptosis,
and genome integrity (Ohmiya et al., 2001).
The aim of our study was to investigate molecular
pathways underlying gastric carcinogenesis by analyz-
ing p53 mutations and MSI status in 62 GC cases and to
determine whether or not there were associations
between these two variables and the traditional clin-
ico-pathological factors, with particular emphasis on
their involvement in the pathogenesis of tumoral
histotype, and also to evaluate their possible predictive
role with regard to the disease-free interval and survival
rate of such patients.
MATERIALS AND METHODS
Clinicopathological variables
Resected specimens from a consecutive series of
62 patients with GC who had undergone potentially
curative surgery were prospectively studied. All
patients were operated on between January 1992 and
December 1996, at the same Institute (Department of
Oncology, University of Palermo, Palermo, Italy).
Clinicopathological factors included: age and sex; tumor
location (cardia or fundus, corpus, and antrum); tumor
size (5 cm and >5 cm); depth of invasion [PS():
invasion into the muscularis propria or into the
subserosa without infiltrative growth; PS(þ): invasion
into the subserosa with infiltrative growth]; TNM stage
(I–IV); node status (negative and positive); histological
grade (G1–G3); histotype (intestinal and diffuse).
None of them had received chemo- or radiotherapy
before surgery. Curative resection included gastrectomy
and extensive dissection of regional lymph nodes. The
resected GC and lymph nodes were examined patholo-
gically and staged according to the latest TNM
classification. Tissue sections from all the 62 surgical
specimens were examined blind by two separate
pathologists (R.M.T. and M.M.). Tumors were classified
according to Lauren’s criteria into intestinal or diffuse
(Lauren, 1965). The grade of differentation was also
evaluated and ranked as G1, G2, and G3 (respectively,
well, moderately, and poorly differentiated). Written
informed consent was obtained from all patients
included in this study.
Patients were followed-up every 3 months for the first
2 years, at six-monthly intervals for the next 2 years and
annually thereafter. All reasonable attempts were made
to document disease relapse (local recurrence or distant
metastases) cytologically or histologically. All patients
with relapse disease after surgery received a standard
chemotherapeutic regimen for GC (5-fluorouracil, epir-
ubicin, methotrexate, etoposide, doxorubicin, and cis-
platin). Information on survival (disease-free survival
(DFS) and overall survival (OS)) was obtained directly
from clinical charts and through the Oncology Section at
our Department. Clinicopathological and follow-up data
of all patients have been recorded prospectively in a
computerized registry database (Table 1).
Tissue-handling and DNA extraction
Multiple samples (3–10) of the primary GC tissue
were taken from different representative areas (includ-
ing the core and the invasive edge of the tumor) and
processed within 30 min of surgical resection. The
portion of primary tumor was obtained by superficial
biopsy of either the tumor bulk or the edge of the
malignant ulcer for more infiltrative cancer. All tissues
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were carefully trimmed to remove as much non-
neoplastic material as possible, avoiding the non-viable
areas. In addition, from each patient multiple samples of
normal-appearing tissue were taken in a corresponding
non-tumoral area as far as possible from the tumor site,
to be used as a standard reference for biomolecular
analyses. Tissues were bisected and one half of each
sample was fixed in 70% ethyl alcohol and paraffin-
embedded for pathological examination; the remaining
half of the sample pool was immediately frozen and
stored at808C until analysis. Histopathological exam-
ination on cryostat sections stained with hemotoxylin
and eosin was then performed; only those samples
containing more than 80% of neoplastic cells were used
for biomolecular studies. Where present, areas with a
high content of non-neoplastic cells were removed from
the frozen block with a scalpel. Evaluation of each
biomolecular variable (p53 and MSI status) was per-
formed independently with no knowledge of clinical
data. Genomic DNA was extracted using the QIAamp
Tissue Kit (Qiagen, Hilden, Germany) with the stan-
dard protocol from primary GC and normal gastric
specimens.
Detection of p53 gene mutations
Mutations within the p53 gene were detected by SSCP
analysis following PCR amplification of the exons 5–8,
performed as described previously (Russo et al., 1998).
In every instance, negative (DNA was replaced with
water) controls were amplified by PCR and included in
the experiment. In all PCR assays, aerosol-resistant
pipette tips were used to avoid cross-contamination. The
quality and the concentration of the amplification
products were verified by 1.5% agarose gel electrophor-
esis and ethidium bromide staining. One hundred
nanogram aliquots of the amplified DNA fragments,
purified and concentrated by filtration through Micro-
con 50 columns (Amicon, Beverly, MA), were denatured
and analyzed by SSCP analysis. PCR-SSCP analysis
was repeated twice for each sample to minimize the
possibility of artifacts due to contamination or polymer-
ase errors and interpretation of SSCP analysis was
performed by consensus of two investigators. DNA of
normal colon tissue from each patient was also amplified
and run in parallel with matched tumoral DNA samples
on SSCP gels, to evaluate the occurrence of germ-line
mutations or polymorphisms. Individual ssDNA frag-
ments with shifted mobilities, compared to normal
control, were electroeluted from polyacrylamide gel, as
described previously (Albanese et al., 1997), reamplified
and sequenced. Automated sequencing was performed
using the Big Dye Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and the model
3100 DNA sequencer (Perkin-Elmer, Foster City, CA).
MSI analysis
Mutations at repetitive tracts were analyzed using a
PCR-based assay. MSI status was assessed at 3 loci by
analyzing markers included in the recommended refer-
ence part of markers for the detection of MSI (the
mononucleotide repeats BAT25, BAT26, and the dinu-
cleotide repeat D2S123). Tumors were classified as MSI-
H when showing contraction(s) in BAT25 and/or BAT26,
regardless of the status of dinucleotide loci, as MSI-L
when instability was limited to dinucleotide loci, and as
MSS when no instability was observed at the loci tested.
Coding repeats within genes involved in the control of
cell proliferation [TGF-bRII poly(A)10, IGFIIR poly(G)8,
RIZ poly(A)9], transcription [TCF4 poly(A)9], apoptosis
[BAX poly(G)8, BCL 10 poly(A)8, FAS poly (T)7, CAS-
PASE5 poly(A)10, APAF1 poly(A)8] and of DNA repair
[hMSH6 poly(C)8, hMSH3 poly(A)8, MED1 poly(A)10,
RAD50 poly(A)9, BLM poly(A)9] were analyzed in the
MSI-H subset. PCR products were directly sequenced
using the Sequenase PCR Sequencing Kit (USB), or
alternatively, after insertion into a plasmid vector with
the Topo TA Cloning Kit (Invitrogen, Carlsbad, CA).
PCRs, electrophoretic separation, and autoradiography
were as described previously (Ottini et al., 1997;
Ottini et al., 1998). Paired genotypings of all cases
positive for microsatellite alterations were confirmed in
duplicate experiments, using independently extracted
DNA samples.
Statistical analysis
Association between p53 mutations, MSI and clinico-
pathological variables was evaluated by means of the
Chi-square test and, where appropriate, Yates’ test.
DFS was measured from the day of primary surgery to
the date of first relapse (locoregional or metastatic) and
OS from the day of surgery to the day of death speci-
fically due to the tumor. If patients did not relapse or die,
they were censored at the time of their last follow-up.
Clinical and morphobiological variables were examined
TABLE 1. Clinicopathologic variables of the 62 gastric cancer
patients
Patients (N)
Sex
Male 42
Female 20
Age
<60 18
60–69 24
>70 20
Site
Antrum 16
Corpus 26
Cardias or fundus 20
Tumor size (cm)
<5 28
>5 34
Tumor type
Intestinal 50
Diffuse 12
Tumor grade
Well differentiated (G1) 4
Mod differentiated (G2) 24
Poorly differentiated (G3) 34
Stage
I 12
II 25
III 21
IV 4
Invasion
PS 37
PSþ 25
Node status
Negative 18
Positive 44
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by means of the Kaplan–Meier method (Kaplan and
Meier, 1958); significance of differences for each prog-
nostic factor was assessed by the logrank and Wilcoxon’s
tests or trend tests where appropriate. Multivariate
analysis was carried out by means of Cox’s proportional
hazards model, using a backward procedure (Cox, 1972).
P-values less than 0.05 were considered statistically
significant.
RESULTS
General outcome
The mean follow-up of patients was of 95 months
(range, 5–137 months). At the time of analysis (Decem-
ber, 2002), 35 patients had relapsed, (of which 1 had
locoregional recurrence and 34 distant metastases),
while 34 had died for tumor-related causes. Overall 5-
year survival rate was of 49.3% (SE 6.9) for the whole
series.
Mutation analysis of p53 gene
Mutation analysis of exons 5–8 of the p53 gene was
performed on genomic DNA from primary GCs of
62 patients. Aberrantly migrating bands were found in
27% (17/62) of the cases (Fig. 1a). Sequence analysis of
the DNA fragments with altered electrophoretic mobi-
lity made it possible to establish the exact site and
nature of the genetic alteration in all tumor samples
(Fig. 1b).
Overall, 20 p53 mutations were identified in 62 of
those screened. The features of the p53 mutations are
summarized in Table 2.
Of the 20 mutations, 45% (9/20) were in exon 5, 20% (4/
20) in exon 6, 20% (4/20) in exon 7, and 15% (3/20) in exon
8. Two tumor samples were found to harbor two (in two
separate exons) or three (in three separate exons)
different p53 mutations. Eighteen of the 20 sequenced
mutations (90%) were found to be missense mutations,
while silent mutations were found in two cases (all of
them in codon 213 [CGA-CGG], a previously identified
site of polymorphism). Moreover, transitions (75%, 15 of
20) were far more frequent than transversions (25%). No
germ-line mutations were found, indicating that in
every case the change was somatic. Fifty percent of the
mutations (10 of 20) occurred in highly conserved
domains (areas II, codons 112–141; area III, codons
171–181; area IV, codons 234–258; area V, codons 271–
286). Accordingly, tumors with p53 mutations were
classified into two groups: 59% of the cases (10/17 cases)
with mutations in conserved areas of the p53 gene
(conserved); 41% (7/17 cases) with mutations outside the
conserved areas (non-conserved). In addition, by taking
into account the specific functional and structural
domains of p53, 30% of mutations (6/20) affected L2
loop (between codons 163 and 195), 20% (4/20) L3
loop (between codons 236 and 251), and 15% (3/20)
LSH motif (between codons 273 and 286), so that the
cases were classified as follows: 4/17 cases (24%) with
mutations of the L3, 3/17 cases (18%) with mutations of
the LSH motif, and 10/17 cases (58%) with mutations
outside L3 and LSH. Since silent mutations do not
determine any aminoacid change in the protein, they
have been included in the wild-type group for statistical
analysis.
Analysis of MSI
MSI analysis was conducted on 56 of the 62 GCs
(because of the DNA exhaustion). By evaluating BAT25
and BAT26, two mononucleotide repeats considered
sensitive indicators of MSI-H status, and D2S123, a
dinucleotide repeat useful to discriminate MSI-L from
MSS cases, 8 tumors (14%) resulted MSI-H, 5 (9%) MSI-
L and 43 (77%) MSS (Table 2). The 8 MSI-H GCs were
analyzed for mutations at coding repeats within genes
involved in the control of cell growth (TGF-bRII, IGFIIR,
RIZ, TCF4), apoptosis (BAX, BCL10, FAS, CASPASE5,
APAF1), and DNA damage repair (hMSH6, hMSH3,
MED1, RAD50, BLM). Mutation frequencies ranged
from 0% to 50% (Table 3). Overall, the most frequently
mutated target genes resulted TGFb-RII and MSH3, in
fact, frameshift mutations at the TGFb-RII poly(A)10
and at the hMSH3 poly(A)8 were observed in 50% MSI-
GCs. Mutation frequencies of 37.5% at the BAX poly(G)8
and BLM poly(A)9, of 25% at the hMSH6 poly(C)8 and
RIZ poly(A)9, of 12.5% at the IGFIIR poly(G)8, at the FAS
poly (T)7 and at the MED1 poly(A)10 were observed in the
MSI-H GCs analyzed.
Multiple target genes were simultaneously mutated
in the majority of the MSI-H GCs (5/8, 62.5%) (Table 3).
Frameshift mutations in coding mononucleotide
repeats consisted mostly in 1-bp deletions (19/23, 83%),
1-bp insertions, and 2-bp deletions were infrequent,
respectively, accounting for 4% (1/23) and 4% (1/23) of
the total number of mutations. Biallelic mutations,
respectively at the TGFb-RII poly(A)10 and at the BAX
poly(G)8, were observed in only two cases (2/23, 8%) and
Fig. 1. SSCP analyses of exon 5 of the p53 gene amplified from
gastric carcinoma and normal-appearing tissue genomic DNA of two
patients (cases 483 and 1,413). In each pair of lanes, the tumor DNA is
at the left (T) and the normal tissue DNA (N) is at the right (a). The
extra bands visualized by arrows in lines 1 and 3 correspond to ssDNA
molecules harboring mutations in codon 176 (TGC to TTC) and 163
(TAC to TGC), as confirmed by sequencing (b). [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
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consisted in 1-bp deletions associated with 1-bp inser-
tions. In the other cases, the occurrence of homozygous
1-bp deletions is unlikely because the wild-type allele
signal was always present, with reduction in intensity
within the 50% range.
Relationship between biomolecular indicators
and clinical data
No association was found between p53 mutations and
MSI status. Nevertheless, considering the presence of
TABLE 2. p53 status, microsatellite instability status, and tumor histotype in the series of the 62 gastric cancer cases
Case p53 status Exon Codon
Nucleotide
change
Aminoacid
change
Conserved
area
Functional
domain MSI status
Tumor
histotype
22 wt MSI-L IT
31 mut 5 175 cgc! ccc arg!pro Area III L2 MSS IT
46 mut 7 244 ggc! gac gly! asp Area IV L3 MSI-L IT
50 wt MSI-H IT
79 wt MSI-H IT
90 wt MSI-L IT
91 wt MSI-L IT
92 wt n.v. IT
128 wt MSS DT
138 mut 5 176 tgc! ttc cys!phe Area III L2 n.v. IT
141 wt MSI-H IT
226 wt MSS IT
236 wt MSS IT
279 wt MSI-H IT
295 wt MSS IT
321 wt MSS IT
340 wt MSS DT
343 wt MSS IT
356 wt MSS IT
376 wt MSS IT
422 wt MSS IT
428 mut 6 195 atc! acc ile! thr Out L2 MSS IT
431 mut 6 214 cat! cgt his! arg Out Out MSS IT
438 mut 5 176 tgc! ttc cys!phe Area III L2 MSS IT
440 mut 7 248 cgg! cag arg! gln Area IV L3 MSS IT
447 wt MSS DT
474 wt MSI-H DT
476 wt MSS DT
483 mut 8 285 gag! aag glu! lys Area V LSH MSS IT
498 wt MSI-H IT
500 wt MSS IT
533 wt MSS IT
561 mut 5 154 ggc! gtc gly! val Out Out MSS IT
599 wt MSS IT
604 wt n.v. IT
621 wt MSS IT
654 wt MSI-H DT
662 wt MSS IT
690 wt MSS DT
699 wt MSS IT
748 wt MSS IT
756 mut 5 157 gtc! ggc val! asp Out Out MSS IT
6 213 cga! cgg arg! arg Out Out MSS IT
7 248 cgg! cag arg! gln Area IV L3 MSS IT
783 wt MSS DT
801 mut 7 249 agg! ggg arg!gly Area IV L3 MSS IT
828 mut 5 152 ccg! cgg pro! arg Out Out MSS IT
6 213 cga! cgg arg! arg Out Out MSS IT
852 wt MSS IT
870 wt MSS IT
890 wt MSI-H IT
969 wt MSS DT
992 mut 8 275 tgt! tat cys! tyr Area V LSH MSS IT
1,003 mut 5 154 ggc! atc gly! ile Out Out MSS IT
1,037 wt MSS IT
1,210 wt MSI-L IT
1,228 wt MSS IT
1,241 wt MSS DT
1,245 mut 5 163 tac! tgc tyr! cys Out L2 MSS IT
1,303 mut 8 276 gcc! acc ala! thr Area V LSH MSS IT
1,340 wt MSS DT
1,373 wt MSS DT
1,395 wt n.v. IT
1,406 wt n.v. IT
1,413 mut 5 163 tac! tgc tyr! cys Out L2 n.v. IT
IT, intestinal type; DT, diffuse type.
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p53 mutations and MSI status, interestingly none of the
eight MSI-H GCs showed p53 mutations whereas one of
the five MSI-L GCs resulted mutated.
In a comparison between these two variables and the
traditional clinico-pathological variables (site, histolo-
gical grade, TNM stage, lymph node metastases), there
was no significant association, except for those between
p53 mutations and tumoral histotype; in fact, all the
17 cases with such mutations were intestinal type
(P< 0.05) (Table 4).
Even when the specific p53 mutations in the con-
served areas or in the functional domains were taken
into consideration, no other associations were observed
with the traditional clinico-pathological variables exam-
ined or with MSI.
Uni- and multivariate analysis
of prognostic factors
At univariate analysis, high TNM stage, node status
positive, depth of invasion (PSþ), diffuse histotype, and
p53 mutations affecting the L3 loop and LSH motif
proved to be significantly related to quicker relapse
(Table 5), whereas these same factors, made exception
for the diffuse histotype, were significantly related to
shorter overall survival (Table 6).
Figure 2 shows the probability of DFS (Fig. 2a) and OS
(Fig. 2b) according to p53 mutations in specific struc-
tural domains. The significant variables at univariate
analysis were entered in a Cox’s proportional hazards
model with backward elimination. The major significant
predictors for both disease relapse and death were high
TNM stage (Tables 5 and 6).
DISCUSSION
In the last few years, several new classification
systems have been formulated for GC according to their
histopathological and, more recently, to biomolecular
features, in order to identify patient subgroups at higher
risk for disease recurrence and death.
With regard to molecular basis of GC, at least two
distinct pathways have been identified: one character-
ized by the successive accumulation of mutations in
oncogenes and tumor suppressor genes, in which p53
plays a relevant role, the other, the MSI pathway,
characterized by the accumulation of somatic alteration
in the length of simple nucleotide repeats that identify a
subset of GC with specific biomolecular features (Fiocca
et al., 2001). Reported data (Renault et al., 1996; Halling
et al., 1999; Iacopetta et al., 1999; Artunedo et al.,
2000; Guo etal., 2000; de Manzoni etal., 2001; Palli etal.,
2001; Sud et al., 2001; Czopek et al., 2002; Huiping et al.,
2002; Inamori et al., 2002; Laghi et al., 2002; Lee et al.,
2002; Takahashi et al., 2002; Yamada et al., 2002) vary
considerably with regard to MSI, ranging from 9.5% to
37.8% in GCs.
These variations may be partly explained by the
differences between susceptible populations and by
different etiological factors, and seem to be clearly link-
ed to the number of cases investigated and to the type
and number of markers used in the study. According to
precise criteria established by several authors (Boland
et al., 1998; Perucho, 1998), the number of GCs with
high MSI (MSI-H) might well be lower, agreeing with
our own results where we found 14% MSI-H GCs, 9%
MSI-L GCs, and 77% MSS GCs.
Mutations in p53 represent one of the critical events in
the development of many human neoplasias (Lutz and
Nowakowska-Swirta, 2002) and are often associated
with the acquisition of greater tumoral invasiveness
(Sakurai et al., 1995). GCs show a variable involvement
of p53 mutations. Reports published in the last few
years, showing a variable p53 mutation rate ranging
from 8% to 55% of the cases (Maesawa et al., 1995; Lim
et al., 1996; Mazaki et al., 1996; Renault et al., 1996;
Ricevuto et al., 1996; Palli et al., 1997; Matturri et al.,
1998; Guo et al., 2000; Park et al., 2001; Wang et al.,
2001; Kubicka et al., 2002; Berloco et al., 2003; Fricke
et al., 2003).
In our own study, 17 of 62 cases studied (27%)
presented p53 mutations, mostly within the conserved
areas (59%) or in domains, which were important for the
functionality of the protein (41% in L3-LSH).
Although several authors report that p53 mutations
tended to be located in the upper portion of stomach,
associated with advanced age (Palli et al., 1997) or with
TABLE 3. Target gene mutations in the eight gastric cancers with high microsatellite instability
Case 50 79 141 279 474 498 654 890
TGFb RII 1del/1ins 1del — — — — 1del 1del
IGFRII — — — — — — — —
RIZ 1ins — — — — — 1del —
TCF4 — — — — — — — —
BAX 1del — — — 1del — 1del/1ins —
BCL10 — — — — — — — —
FAS — — — — — — — —
CASP5 — — — — — — — —
APAF1 — — — — — — — —
hMSH6 — — — — — 1del 1del —
hMSH3 1del 1del — — — 1del — 1del
MED1 2del — — — — — — —
RAD50 — — — — — — — —
BLM 1del 1del — — — — 1del —
TABLE 4. Relationships of p53 status and tumor histotype of the
62 gastric cancer patients
p53
PNo mutation (%) Mutation (%)
Tumor histotype
Intestinal 33 (73) 17 (100)
Diffuse 12 (27) 0 (0) <0.05
Total 45 (72) 17 (28)
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advanced stage (Guo et al., 2000); in our own cases, we
did not find any significant association between p53
mutations and the traditional clinicopathological vari-
ables (age, sex, site and size of the tumor, stage, grading,
invasiveness). Moreover, we found no association
between these variables and MSI-H, in spite of the fact
that several authors have reported higher MSI in
intestinal-type tumors (Simpson et al., 2001), in distal
(antral) tumors (Ottini et al., 1997), in tumors without
lymph node metastases (Huiping et al., 2002; Lee et al.,
2002), or in elderly or female patients (Iacopetta et al.,
1999; Yamada et al., 2002).
It may often happen that at advanced stages, both
histological types (IT and DT) present the same type of
genetic alterations (Tamura, 2002), for instance, muta-
tions in APC, KRAS2, p53, or MSI, which are brought
about by early events in differentiated GCs. On the other
hand, where GCs have developed first as an undiffer-
entiated tumors, they rarely seem to be prone to these
types of alterations.
In our own cases, we also found a more frequent high
MSI in IT tumors (six of eight MSI-H cases), together
with a significant association between p53 mutations
and intestinal histotype. In fact, none of the 12 diffuse-
type GCs showed p53 alterations (Table 4). These data
support the idea that p53 mutations and other specific
genetic alterations might be behind the development of
intestinal- but not of diffuse-type GCs.
Moreover, as already reported by several other
authors (Endoh et al., 2000; Guo et al., 2000), none of
the MSI-H cases presented p53 mutations, which
suggests that alterations in the DNA repair mechan-
isms, which give rise to MSI, and p53 mutations may be
mutually exclusive indicating the existence of distinct
TABLE 5. Kaplan–Meier and Cox’s proportional hazards analysis of clinico-pathologic and biological variables to predict the hazard ratio of
relapse in gastric cancer patients
Variables Pts (N)
Univariate Multivariate
DFS (%) 2 years DFS (%) 5 years O/E P RR CI (95%) b P
Histotype
Intestinal 50 76 58 0.83
Diffuse 12 33 11 2.452 <0.01
TNM stage
I 12 100 92 0.19 1
II 25 80 55 0.90 4.93 1.12–21.6 1.59 <0.05
III–IV 25 38 19 2.25 <0.01 13.9 3.14–61.7 2.63 <0.01
Depth of invasion
PS () 37 78 59 0.65
PS (þ) 25 50 34 1.82 <0.01
Node status
Node negative 18 89 83 0.55
Node positive 44 59 34 1.33 <0.05
P53
wt 45 69 55 0.94
mut outside L3/LSH 10 70 70 0.55
mut in L3-LSH 7 57 0 2.35 <0.05
Total pts 62 68 51
Pts, patients; O/E, observed/expected; RR, relative risk; CI, confidence interval; PS(), invasion into the muscularis propria or into the subserosa without infiltrative
growth; PS(þ), invasion into the subserosa with infiltrative growth.
TABLE 6. Kaplan–Meier and Cox’s proportional hazards analysis of clinicopathologic and biological variables to predict death in gastric cancer
patients
Variables Pts (N)
Univariate Multivariate
OS (%), 3 years OS (%), 5 years O/E P RR CI (95%) b P
TNM stage
I 12 100 91 0.20 1
II 25 75 57 0.85 4.50 1.02–19.9 1.50 <0.05
III–IV 24 36 15 2.42 <0.01 14.3 3.25–63.5 2.66 <0.01
Depth of invasion
PS () 37 78 60 0.61
PS (þ) 24 46 30 1.99 <0.01
Node status
Node negative 18 89 83 0.55
Node positive 43 56 33 1.33 <0.05
P53
wt 44 66 56 0.93
mut outside L3/LSH 10 76 61 0.59
mut in L3-LSH 7 57 0 2.33 <0.05
Total pts 61 66 49
See Table 4 for abbreviations.
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cancerogenetic pathways for GC (Fiocca et al., 2001). In
this respect, it is noteworthy that the majority of MSI-H
GCs showed frameshift mutations in genes controlling
cellular growth, apoptosis, and DNA repair thus
conferring a selective advantage independently of p53
mutations.
In several previous studies (Lim et al., 1996; Yama-
moto et al., 1999; Kubicka et al., 2002), the presence of
MSI-H has been associated with a more favorable
outcome in GC patients; we ourselves, however, in
concordance with several other authors (Renault et al.,
1996; Halling et al., 1999; Iacopetta et al., 1999;
Artunedo et al., 2000; Guo et al., 2000; Palli et al.,
2001;Sud etal., 2001;Huiping etal., 2002; Inamori etal.,
2002; Lee et al., 2002; Takahashi et al., 2002; Yamada
et al., 2002) did not find such an association.
Contradictory findings have been reported (El-Rifai
and Powell, 2002) with regard to the presence of p53
alterations and the prognosis of GC patients. A great
many studies, however, have used immunohistochem-
ical analysis to detect overexpression of p53 as an
indirect means of evaluating mutations of this gene, and
this assay does not appear to have consistent prognostic
significance in GC patients (Fenoglio-Preiser et al.,
2003). The few studies so far conducted to evaluate the
prognostic impact of p53 mutations in GCs do not appear
to provide any further information regarding this aspect
(Lim et al., 1996; Matturri et al., 1998; Kubicka et al.,
2002).
In the present study, no significant difference was
observed in survival rate between GC patients with such
mutations and those without. Nevertheless, since the L3
loop and the LSH motif of p53 contain residues involved
in direct DNA contact and in protein stabilization, any
alteration within these domains will affect this critical
DNA contact and may have a negative influence on
cancer therapy involving p53-dependent programmed
cell-death (leading to treatment-resistant tumors). This
fact suggests that specific mutations may be biologically
more significant in terms of disease recurrence and the
overall survival rate of patients. Previous studies
involving other types of human neoplasias have shown
Fig. 2. DFS (a) and OS (b) of 62 patients with GC according to p53 functional and structural domains.
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that specific mutations in the conserved areas of the
gene or in the functional domains, as defined by cry-
stallography (Cho et al., 1994), may have more prog-
nostic significance than overall p53 mutations (Borresen
et al., 1995; Borresen-Dale et al., 1998; Skaug et al.,
2000; Russo et al., 2002).
In this study, univariate analysis shows that patients
affected by tumors with p53 mutations in the functional
domains L3 and LSH have a considerably shorter DFS
and OS period (Tables 5 and 6). Nevertheless, these
mutations would seem to be less significant predictive
variables than tumor stage (P<0.05 vs. P<0.01), since
Cox’s proportional hazards analysis demonstrates that
only the latter can be considered as significant prog-
nostic factors (OS and DFS) (Tables 5 and 6).
CONCLUSION
Although the role of molecular alterations in GC still
remains to be fully defined, it now seems more or less
clear that tumors which are apparently identical from
the morphological point of view should not be treated as
a single type of neoplasia and that biomolecular
investigation can help in the choice of a more specific
and accurate therapeutic approach. Our study appar-
ently confirms the existence of two different tumorige-
netic pathways between intestinal and the diffuse type
GCs. Moreover, there would seem to be two different,
mutually exclusive, tumorigenesis profiles within dif-
ferent, intestinal-type GCs, one involving p53 mutations
and the other alterations of the DNA repair system
which accompany MSI.
The role of p53 mutations and MSI-H in the outcome of
GC patients, however, is still not fully understood,
although our own study seems to suggest that specific
mutations in functional domains of p53, rather than any
mutations in this gene, may be biologically more
significant in terms of disease recurrence and the overall
survival rate of patients. If future studies involving a
larger number of cases confirm this finding, together
with that regarding traditional variables with con-
firmed prognostic impact (TNM stage), specific p53
mutations may help to identify subgroups of patients at
higher risk of relapse or death who might benefit from a
more aggressive therapeutic approach.
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